Field guide · Ibogaine
How to vet an ibogaine clinic.
Ibogaine is serious medicine, and it is hard on the heart. The clinics that give it answer to no single standard. This is the record: what the research shows about risk, what careful clinics screen for, how they monitor, and where treatment is legal. Take the questions with you.
The questions to ask
A clinic that answers these plainly has done the work.
- Do you take a resting 12-lead ECG before intake, and repeat it on arrival?
- Do you test electrolytes, magnesium and liver function, and correct them first?
- Do you review every medication, supplement and street drug I use, in writing?
- Who watches my heart during the first 24 hours, and what are their qualifications?
- Is there a heart monitor per patient, a defibrillator, oxygen and IV access in the room?
- How far are you from emergency responders and a 24-hour hospital, and what is your plan?
- What is the legal status of ibogaine where you operate?
What the research says about ibogaine and the heart
A systematic review of every known fatality outside West Central Africa temporally linked to ibogaine from 1990 to 2008 found 19 deaths, occurring 1.5 to 76 hours after ingestion.
In that review, pre-existing medical conditions (mainly cardiovascular) and/or other drugs explained or contributed to death in 12 of the 14 cases with adequate postmortem data; seizures from alcohol or benzodiazepine withdrawal and uninformed use of plant forms were other apparent risk factors.
Laboratory work shows ibogaine blocks hERG potassium channels in the heart, a proposed mechanism for life-threatening arrhythmias.
A 2015 review in Molecules notes ibogaine is not a licensed drug but is used in dozens of clinics worldwide, and that reports of life-threatening complications and sudden deaths have accumulated.
A 2021 systematic review of adverse events (2015 to 2020) found the most common acute adverse event was QTc prolongation, alongside long-lasting cardiac, psychiatric and neurological effects, and called for phase I trials and better screening methods.
In a monitored Dutch university-hospital study of 14 people with opioid use disorder, half reached a QTc above 500 ms and in six the prolongation above 450 ms lasted beyond 24 hours; the authors describe clinically relevant but reversible QTc prolongation, slow heart rate and severe ataxia.
Case reports describe cardiac arrest after ibogaine, including a fatal case following use for heroin withdrawal and a survived case in which QT took seven days to normalize because of ibogaine's long half-life.
The Stanford team behind the 2024 Nature Medicine veterans study wrote that high doses, pre-existing conditions, drug-drug interactions and lack of vital-sign monitoring may have played critical roles in past fatal arrhythmias.
In a 12-month New Zealand observational study of legal ibogaine treatment, one enrolled patient died during treatment.
Health Canada says it has received serious and fatal adverse reaction reports associated with ibogaine and issued a public risk communication in 2015.
A 2022 systematic review of 24 clinical studies (705 people) found evidence of benefit for substance use disorders but also severe complications and deaths linked to neuro- and cardiotoxic effects, and said rigorous study designs within medical settings are needed.
The 2024 Stanford / Nature Medicine study of veterans (magnesium-ibogaine)
Stanford researchers published a prospective observational study in Nature Medicine (January 2024) of 30 male Special Operations veterans with mostly mild traumatic brain injury who received ibogaine with magnesium (the MISTIC protocol) at a clinic in Mexico.
The authors say ibogaine has been linked to fatal arrhythmia and that co-giving magnesium 'may mitigate' this; they report no unexpected or serious adverse events in their sample.
The study was open-label and not randomized; the authors say controlled trials are needed and that expectancy or the other on-site therapies may explain some benefit.
Stanford did not administer the ibogaine; the Mexican clinic did its own screening and treatment. Some authors hold patents or are shareholders in the treating clinic.
The trial is registered on ClinicalTrials.gov as NCT04313712 (Stanford University), listed as active, not recruiting.
The authors' own conclusion ties safety to screening, precautions and medical monitoring, not to ibogaine alone.
What medical screening published protocols describe
The GITA guidelines call careful screening the most important factor in reducing risk, and ask for a full medical history plus a complete list of medications, supplements and street drugs before intake.
Tests GITA lists include a resting 12-lead ECG; further cardiac testing (stress test, echocardiogram or Holter monitor) when warranted; a complete metabolic panel covering electrolytes, magnesium and liver function; a complete blood count; thyroid testing; and a physical exam.
GITA lists absolute exclusions, including a prolonged QTc interval, history of heart failure or an enlarged heart, active blood clots, certain psychiatric conditions such as schizophrenia, epilepsy, and pregnancy.
GITA says potassium or magnesium outside normal ranges should be corrected, and flags impaired liver or kidney function as a risk because the body may not clear ibogaine properly.
GITA lists cardiac risk factors (such as borderline QTc, arrhythmias, prior heart attack, and family history of sudden cardiac death before 50) that call for a risk-benefit review by a cardiologist familiar with ibogaine.
In the Stanford study, the treating clinic's screening included routine blood work and an ECG, and it told patients to stop medicines with concerning interactions, including CYP2D6 inhibitors, serotonergic drugs, beta-blockers, benzodiazepines, stimulants and all psychiatric medications.
The Stanford study excluded people with a history of cardiovascular, liver or kidney problems, psychotic disorders, or significant suicide risk.
Ibogaine is converted to its active metabolite mainly by the liver enzyme CYP2D6. In healthy volunteers, blocking that enzyme with paroxetine roughly doubled exposure, which is why interacting medicines and metabolizer status come up in screening.
For people who use opioids, GITA warns that ibogaine can intensify opioid effects if they are taken together, that long-acting opioids like methadone or buprenorphine need special handling, and that tolerance is lost afterward, raising overdose risk on relapse.
GITA describes a second screening on arrival: a repeat ECG and a urine test for pregnancy and substances, noting that standard tests miss fentanyl, oxycodone and buprenorphine unless specifically requested.
What monitoring, staffing and emergency access are described
GITA recommends that all caregivers hold at least Basic Life Support certification, and that ACLS-trained, equipped medical staff be present throughout treatment.
GITA says treatment outside a hospital should be within 15 minutes of fully equipped emergency responders and ideally within 30 minutes of a 24-hour hospital, with a rehearsed emergency plan.
During the first 12 to 24 hours, GITA describes continuous heart monitoring with an ACLS-trained staff member watching cardiac changes and a second on hand for emergencies.
GITA describes lighter supervision for at least 72 hours afterward because cardiac risk remains, with regular checks of blood pressure, pulse and oxygen and an ACLS-trained person available, and says patients should not normally be discharged before 72 hours.
GITA's recommended equipment list includes a heart monitor per patient, an AED or defibrillator, oxygen, IV access supplies, a blood pressure cuff, a pulse oximeter, and a crash cart with ACLS medications including magnesium sulfate.
GITA recommends an IV line stay in place until a physician confirms cardiac risk has passed, both for fluids and for emergency medicines in case of arrhythmia or seizure.
In the Stanford study, ACLS-certified medical staff (MD, RN or EMT) were on site at a ratio of at least one per two patients, with continuous 5-lead ECG monitoring of the QTc for 12 to 16 hours; clinic staff also re-checked blood work, ECG and urinalysis on arrival.
In the Stanford study, all participants had temporary ataxia and tremor that resolved within 24 hours; some were treated for headache, nausea, anxiety or high blood pressure.
GITA says patients should be told, before arrival and in writing, the legal status of ibogaine where treatment happens, its experimental status, the risks, the caregivers' experience and qualifications, realistic benefits, and alternatives.
Where ibogaine treatment is legally offered or regulated
United States: ibogaine is a Schedule I controlled substance under federal law. It is available only in research, for example the trials listed on ClinicalTrials.gov.
Mexico: the Stanford Nature Medicine paper describes Mexico as a place where ibogaine use is not restricted. No Mexican government source was verified.
New Zealand: the medicines regulator's classification committee recommended in November 2009 that ibogaine and noribogaine be classified as prescription medicines, and a 2018 study describes legal ibogaine treatment there.
Brazil: a 2014 peer-reviewed study described ibogaine as unregulated in Brazil, with treatment combining physician supervision and psychotherapy. This is dated and no current Brazilian government source was verified.
Canada: ibogaine is not authorized for use. Since 2017 it has been on Health Canada's Prescription Drug List, which restricts sale to prescription and limits compounding.
Registered ibogaine studies have also run outside the US, for example an open-label alcoholism trial at the University of Sao Paulo (Brazil), a methadone-detoxification study in Spain, and a study of oral ibogaine for opioid withdrawal in the UK.
US helplines
SAMHSA's National Helpline, 1-800-662-HELP (4357), is a free, confidential, 24/7 treatment referral and information service in English and Spanish. TTY is 1-800-487-4889.
The SAMHSA helpline does not provide counseling. It refers callers to local services, and people can also text their ZIP code to 435748 (HELP4U).
The 988 Suicide & Crisis Lifeline (call, text or chat 988) is free, confidential and available 24/7, including for alcohol or drug use concerns.
Checked 2026-09-22. Every line traces to the page it came from; hover a source to read the quote.